These two genes, as well as MS4A4A and MS4A6A, are highly expressed in microglia and are transmembrane proteins, suggesting that may affect the proteolytic cleavage of TREM2 and serve as novel therapeutic targets for AD. The gene discussed is TREM2; the disease is Alzheimer disease.